The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model

Diabetes

Volumn 66, Issue 4, 2017, Pages 1030-1040

  Joubert, Michael ^a,b,c   Jagu, Benoît ^a   Montaigne, David ^d   Marechal, Xavier ^d   Tesse, Angela ^a   Ayer, Audrey ^a   Dollet, Lucile ^a   Le May, Cédric ^a   Toumaniantz, Gilles ^a   Manrique, Alain ^c   Charpentier, Flavien ^a   Staels, Bart ^d   Magré, Jocelyne ^a   Cariou, Bertrand ^a   Prieur, Xavier ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c GIP CYCERON   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEXOSAMINE; MESSENGER RNA; PIOGLITAZONE; TRANSCRIPTION FACTOR FKHR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BSCL2 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; RADIOPHARMACEUTICAL AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; GLUCOSE TRANSPORT; GLUCOTOXICITY; HEART LEFT VENTRICLE FAILURE; HYPERGLYCEMIA; HYPERTROPHIC CARDIOMYOPATHY; INSULIN RESISTANCE; LIPODYSTROPHY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME ULTRASOUND SCANNER; SYSTOLIC DYSFUNCTION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENETICS; GLUCOSE BLOOD LEVEL; HEART; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FUNCTION; KNOCKOUT MOUSE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CARDIOMYOPATHY, HYPERTROPHIC; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FLUORODEOXYGLUCOSE F18; GLUCOSIDES; HEART; HETEROTRIMERIC GTP-BINDING PROTEINS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPODYSTROPHY; MAGNETIC RESONANCE IMAGING; MICE; MICE, KNOCKOUT; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION;

EID: 85019618220     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0733     Document Type: Article

References (58)

1. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002;105:1727-1733
2. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002;105:1861-1870
3. MacDonald MR, Jhund PS, Petrie MC, et al. Discordant short-And long-Term outcomes associated with diabetes in patients with heart failure: importance of age and sex: A population study of 5.1 million people in Scotland. Circ Heart Fail 2008;1:234-241
4. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602
5. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718-1727
6. Abel ED, OShea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012;32:2068-2076
7. Labbé SM, Grenier-Larouche T, Noll C, et al. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012;61:2701-2710
8. Drosatos K, Schulze PC. Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 2013;10:109-121
9. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010; 1801:311-319
10. Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009;119:1272-1283
11. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta 2016;1860:1555-1568
12. Kolwicz SC Jr, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 2011;90:194-201
13. Mazumder PK, ONeill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366-2374
14. Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013;305:H1693-H1697
15. Montaigne D, Marechal X, Coisne A, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 2014;130:554-564
16. Magré J, Delépine M, Khallouf E, et al.; BSCL Working Group. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001;28:365-370
17. Garg A. Clinical review. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011;96:3313-3325
18. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: A clinical assessment. Medicine (Baltimore) 2010;89:245-250
19. Rheuban KS, Blizzard RM, Parker MA, Carter T, Wilson T, Gutgesell HP. Hypertrophic cardiomyopathy in total lipodystrophy. J Pediatr 1986;109: 301-302
20. Jeninga EH, de Vroede M, Hamers N, et al. A patient with congenital generalized lipodystrophy due to a novel mutation in BSCL2: indications for secondary mitochondrial dysfunction. JIMD Rep 2012;4:47-54
21. Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 2013;112:1019-1024
22. Cui X, Wang Y, Tang Y, et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet 2011;20:3022-3030
23. Chen W, Chang B, Saha P, et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-Autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol 2012;32:1099-1111
24. Prieur X, Dollet L, Takahashi M, et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia 2013;56:1813-1825
25. Royer A, van Veen TA, Le Bouter S, et al. Mouse model of SCN5A-linked hereditary Lenègres disease: Age-related conduction slowing and myocardial fibrosis. Circulation 2005;111:1738-1746
26. Joubert M, Hardouin J, Legallois D, et al. Effects of glycaemic variability on cardiac remodelling after reperfused myocardial infarction: evaluation of streptozotocin-induced diabetic Wistar rats using cardiac magnetic resonance imaging. Diabetes Metab 2016;42:342-350
27. Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 1990;81:1594-1605
28. Bugger H, Boudina S, Hu XX, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008;57: 2924-2932
29. Galgani JE, Vasquez K, Watkins G, et al. Enhanced skeletal muscle lipid oxidative efficiency in insulin-resistant vs insulin-sensitive nondiabetic, nonobese humans. J Clin Endocrinol Metab 2013;98:E646-E653
30. Montaigne D, Marechal X, Baccouch R, et al. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol Appl Pharmacol 2010;244:300-307
31. Brown MA, Myears DW, Bergmann SR. Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. J Nucl Med 1989;30: 187-193
32. Brown MA, Myears DW, Bergmann SR. Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol 1988;12:1054-1063
33. Welch MJ, Lewis JS, Kim J, et al. Assessment of myocardial metabolism in diabetic rats using small-Animal PET: A feasibility study. J Nucl Med 2006;47: 689-697
34. Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab 2010;36:423-435
35. van den Brom CE, Huisman MC, Vlasblom R, et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 2009;8:39
36. Chen W, Zhou H, Saha P, Li L, Chan L. Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology 2014;155:4215-4225
37. Cui X, Wang Y, Tang Y, et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet 2011;20:3022-3030
38. Kaczmarczyk SJ, Andrikopoulos S, Favaloro J, et al. Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 2003;31:449-459
39. Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol 2015;6:331-351
40. Grassi I, Nanni C, Allegri V, et al. The clinical use of PET with (11)C-Acetate. Am J Nucl Med Mol Imaging 2012;2:33-47
41. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009;2:454-466
42. Shoghi KI, Gropler RJ, Sharp T, et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: A small-Animal PET investigation. J Nucl Med 2008;49:1320-1327
43. Dolinsky VW, Dyck JR. Role of AMP-Activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 2006;291:H2557-H2569
44. Dassanayaka S, Jones SP. O-GlcNAc and the cardiovascular system. Pharmacol Ther 2014;142:62-71
45. Marsh SA, DellItalia LJ, Chatham JC. Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 2011;40: 819-828
46. Young ME, Yan J, Razeghi P, et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio 2007;1:251-262
47. Fricovsky ES, Suarez J, Ihm SH, et al. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 2012;303:R689-R699
48. Banerjee PS, Ma J, and Hart GW. Diabetes-Associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc Natl Acad Sci U S A 2015;112: 6050-6055
49. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. O-GlcNAc modification of FoxO1 increases its transcriptional activity: A role in the glucotoxicity phenomenon? Biochimie 2008;90:679-685
50. Issad T, Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008;19:380-389
51. Battiprolu PK, Hojayev B, Jiang N, et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012;122:1109-1118
52. Chang CS, Tsai PJ, Sung JM, Chen JY, Ho LC, Pandya K, Maeda N, and Tsai YS. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol 2014;184:442-453
53. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221-1238
54. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752-772
55. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: A "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-1114
56. Mailleux F, Gélinas R, Beauloye C, Horman S, Bertrand L. O-GlcNAcylation, enemy or ally during cardiac hypertrophy development? Biochim Biophys Acta 2016;1862:2232-2243
57. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
58. Hong EG, Jung DY, Ko HJ, et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007;293:E1687-E1696